WILMINGTON, Del. & HANGZHOU --(BUSINESS WIRE)— Arbella Therapeutics, LLC. (“Arbella”), a U.S. early stage biotechnology company focused on the discovery and development of innovative small molecule therapies, and Hangzhou Polymed Biopharmaceuticals (“Polymed”), a leading biopharmaceutical company in China, have announced a collaboration to develop and commercialize ARB-085 – a preclinical development candidate targeting dual EGFR and HER2 Exon 20 mutations – in Greater China and South Korea.

Under the terms of the collaboration, Arbella is eligible to receive an upfront collaboration fee and additional payments contingent on certain development and regulatory milestones, plus royalties on net product sales. Polymed will lead the development and commercialization of ARB-085 in Greater China.

“We are glad to have begun this partnership with Polymed to progress ARB-085 in China, where there is a significant unmet medical need for the treatment of non-small cell lung cancer caused by genetic mutations. We look forward to working in close collaboration with Polymed to continue the development of ARB-085 as we progress toward the clinical stage,” said Fred Martin, Ph.D., Founder and Manager of Arbella.

“We look forward to a successful collaboration with Arbella for developing ARB-085,” said Dr. Jason Shaoyun Xiang, the founder and CEO of Polymed. “In addition to pushing forward highly innovative internal PROTAC projects, Polymed is leveraging its capabilities for collaboration with leading world-class institutions to bring urgently-needed therapeutics into clinical development”, said Dr. Xiang.

Discovered through research conducted in collaboration with the Dana-Farber Cancer Institute (“DFCI”) of Harvard University, ARB-085 is a potent and selective dual EGFR/HER2 Exon 20 insertion inhibitor for non-small cell lung cancers, currently in preclinical stage.

Polymed Biopharmaceuticals is a novel drug discovery and development company based in Hangzhou, China and Boston, USA. The company focuses on first-in-class and best-in-class products in the areas of oncology and auto-immune diseases. The company is utilizing modern technology including artificial intelligence and structural biology to support the drug discovery process. The business goal is to identify breakthrough medicines through either traditional enzyme inhibition mechanism or modern protein degradation approach such as PROTAC technology. The company has a rich and sustainable project pipeline and also seeks international collaborations. For more information, please visit https://www.polymedbiopharma.com/

Arbella Therapeutics is an early stage biotechnology company focused on discovering and developing innovative small molecule oncology therapies to help patients with severe unmet medical needs. Arbella was established in 2015 to develop best-in-class medicines targeting cancers for which current targeted therapies are ineffective. Arbella also has the goal of making novel, innovative, and targeted therapies more affordable than is typically the case for new oncology treatments, and therefore more widely available. Working together with scientists at several research institutions, Arbella’s team has developed a promising pipeline, with multiple compounds in discovery to preclinical stages.

For more information, please visit http://Arbellatherapeutics.com/[Note: In progress ]
Contacts
For Polymed:
Jason Xiang, jasonxiang@polymedbiopharma.com
For Arbella Therapeutics:
Fred Martin, martin@bancroftgroup.com